Concepts (110)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acceptance and Commitment Therapy | 4 | 2026 | 16 | 2.160 |
Why?
|
| Chronic Pain | 4 | 2025 | 157 | 1.860 |
Why?
|
| Pain Management | 4 | 2025 | 174 | 1.750 |
Why?
|
| Veterans | 12 | 2026 | 761 | 1.690 |
Why?
|
| Psychiatry | 1 | 2025 | 129 | 0.780 |
Why?
|
| Opioid-Related Disorders | 4 | 2025 | 529 | 0.450 |
Why?
|
| Tobacco Use Cessation | 2 | 2026 | 32 | 0.420 |
Why?
|
| Self-Management | 2 | 2025 | 72 | 0.410 |
Why?
|
| Social Support | 3 | 2025 | 393 | 0.400 |
Why?
|
| Health Services Accessibility | 3 | 2025 | 599 | 0.320 |
Why?
|
| Community Integration | 3 | 2018 | 7 | 0.310 |
Why?
|
| Mental Disorders | 3 | 2026 | 822 | 0.290 |
Why?
|
| Adult | 14 | 2026 | 17460 | 0.260 |
Why?
|
| Opiate Substitution Treatment | 2 | 2025 | 224 | 0.240 |
Why?
|
| United States Department of Veterans Affairs | 5 | 2025 | 542 | 0.230 |
Why?
|
| Equivalence Trials as Topic | 1 | 2025 | 17 | 0.230 |
Why?
|
| Humans | 24 | 2026 | 65462 | 0.230 |
Why?
|
| Antiretroviral Therapy, Highly Active | 4 | 2005 | 94 | 0.220 |
Why?
|
| Acute Pain | 1 | 2025 | 20 | 0.220 |
Why?
|
| Internet | 2 | 2026 | 472 | 0.220 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 2020 | 405 | 0.210 |
Why?
|
| Buprenorphine | 3 | 2025 | 198 | 0.210 |
Why?
|
| Pain Measurement | 1 | 2025 | 343 | 0.210 |
Why?
|
| Employment | 1 | 2025 | 132 | 0.200 |
Why?
|
| Male | 14 | 2026 | 31186 | 0.200 |
Why?
|
| Pilot Projects | 2 | 2024 | 1021 | 0.190 |
Why?
|
| Feasibility Studies | 1 | 2024 | 589 | 0.180 |
Why?
|
| Female | 13 | 2026 | 34193 | 0.180 |
Why?
|
| Analgesics, Opioid | 2 | 2025 | 529 | 0.180 |
Why?
|
| Transgender Persons | 1 | 2022 | 68 | 0.180 |
Why?
|
| Sexual and Gender Minorities | 1 | 2022 | 76 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2025 | 808 | 0.170 |
Why?
|
| Conjunctivitis, Allergic | 1 | 2021 | 2 | 0.170 |
Why?
|
| Anti-Allergic Agents | 1 | 2021 | 4 | 0.170 |
Why?
|
| Naltrexone | 2 | 2021 | 91 | 0.170 |
Why?
|
| Middle Aged | 11 | 2026 | 18386 | 0.170 |
Why?
|
| Smoking Cessation | 1 | 2026 | 553 | 0.160 |
Why?
|
| Cross-Sectional Studies | 3 | 2025 | 2721 | 0.160 |
Why?
|
| Reproducibility of Results | 1 | 2025 | 1710 | 0.160 |
Why?
|
| Mental Health | 2 | 2023 | 364 | 0.160 |
Why?
|
| Narcotic Antagonists | 2 | 2021 | 133 | 0.160 |
Why?
|
| United States | 11 | 2025 | 8148 | 0.150 |
Why?
|
| Pandemics | 1 | 2023 | 682 | 0.140 |
Why?
|
| Robotics | 1 | 2019 | 86 | 0.140 |
Why?
|
| Rehabilitation, Vocational | 1 | 2018 | 32 | 0.140 |
Why?
|
| Self-Help Groups | 1 | 2018 | 37 | 0.140 |
Why?
|
| Employment, Supported | 1 | 2018 | 21 | 0.140 |
Why?
|
| Quality of Life | 1 | 2025 | 1263 | 0.130 |
Why?
|
| Education | 1 | 2018 | 66 | 0.130 |
Why?
|
| Substance-Related Disorders | 1 | 2025 | 755 | 0.130 |
Why?
|
| Surveys and Questionnaires | 1 | 2025 | 2776 | 0.130 |
Why?
|
| AIDS-Related Opportunistic Infections | 3 | 2005 | 67 | 0.130 |
Why?
|
| Treatment Outcome | 2 | 2025 | 5806 | 0.120 |
Why?
|
| Aged | 7 | 2025 | 15051 | 0.120 |
Why?
|
| Adaptation, Psychological | 1 | 2018 | 279 | 0.120 |
Why?
|
| Emergency Service, Hospital | 1 | 2023 | 1161 | 0.110 |
Why?
|
| Ambulatory Care | 3 | 2005 | 317 | 0.110 |
Why?
|
| Qualitative Research | 2 | 2026 | 757 | 0.080 |
Why?
|
| Methadone | 2 | 2025 | 140 | 0.080 |
Why?
|
| HIV Infections | 3 | 2005 | 958 | 0.080 |
Why?
|
| Veterans Health | 2 | 2024 | 145 | 0.080 |
Why?
|
| Injections, Intramuscular | 2 | 2021 | 71 | 0.080 |
Why?
|
| Hospitalization | 2 | 2005 | 1399 | 0.070 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 2005 | 8 | 0.060 |
Why?
|
| Young Adult | 3 | 2022 | 4836 | 0.060 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2005 | 19 | 0.060 |
Why?
|
| Self-Control | 1 | 2025 | 10 | 0.060 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 1 | 2025 | 89 | 0.060 |
Why?
|
| Social Stigma | 1 | 2025 | 79 | 0.050 |
Why?
|
| Health Resources | 1 | 2005 | 92 | 0.050 |
Why?
|
| Behavior Therapy | 1 | 2025 | 169 | 0.050 |
Why?
|
| Hospitals, Military | 1 | 2023 | 4 | 0.050 |
Why?
|
| Multivariate Analysis | 4 | 2005 | 931 | 0.050 |
Why?
|
| Exercise Therapy | 1 | 2024 | 102 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2023 | 6929 | 0.040 |
Why?
|
| Ophthalmic Solutions | 1 | 2021 | 8 | 0.040 |
Why?
|
| Buprenorphine, Naloxone Drug Combination | 1 | 2021 | 26 | 0.040 |
Why?
|
| Allergens | 1 | 2021 | 54 | 0.040 |
Why?
|
| Confidence Intervals | 3 | 2005 | 237 | 0.040 |
Why?
|
| Delayed-Action Preparations | 1 | 2021 | 120 | 0.040 |
Why?
|
| Caregivers | 1 | 2024 | 296 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2021 | 213 | 0.040 |
Why?
|
| Odds Ratio | 3 | 2005 | 755 | 0.040 |
Why?
|
| Mental Health Services | 1 | 2023 | 305 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2021 | 743 | 0.040 |
Why?
|
| Cohort Studies | 4 | 2005 | 2632 | 0.040 |
Why?
|
| Mobile Applications | 1 | 2019 | 140 | 0.030 |
Why?
|
| Peer Group | 1 | 2018 | 114 | 0.030 |
Why?
|
| Workplace | 1 | 2018 | 177 | 0.030 |
Why?
|
| Family | 1 | 2018 | 248 | 0.030 |
Why?
|
| Counseling | 1 | 2018 | 376 | 0.030 |
Why?
|
| Aged, 80 and over | 4 | 2005 | 5643 | 0.030 |
Why?
|
| Comorbidity | 1 | 2017 | 1120 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2021 | 3325 | 0.030 |
Why?
|
| Patient Admission | 2 | 2005 | 199 | 0.020 |
Why?
|
| Length of Stay | 2 | 2005 | 828 | 0.020 |
Why?
|
| Poisson Distribution | 1 | 2005 | 52 | 0.010 |
Why?
|
| Medical Records | 1 | 2005 | 140 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2005 | 252 | 0.010 |
Why?
|
| Sampling Studies | 1 | 2005 | 65 | 0.010 |
Why?
|
| Health Care Surveys | 1 | 2005 | 288 | 0.010 |
Why?
|
| Primary Prevention | 1 | 2005 | 137 | 0.010 |
Why?
|
| Health Services Needs and Demand | 1 | 2005 | 220 | 0.010 |
Why?
|
| Poverty | 1 | 2005 | 307 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2005 | 213 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2005 | 804 | 0.010 |
Why?
|
| Logistic Models | 1 | 2005 | 1273 | 0.010 |
Why?
|
| Primary Health Care | 1 | 2005 | 723 | 0.010 |
Why?
|
| Risk Factors | 1 | 2005 | 5459 | 0.010 |
Why?
|
| Adolescent | 1 | 2005 | 6332 | 0.010 |
Why?
|